Brazil BRL Currency Depreciation
BRL depreciated 17% this quarter, causing ~2% impact on consolidated revenue. Management expects this headwind to continue for another 1-2 quarters, affecting near-term reported growth.
TORNTPHARM / Q3-FY25 / risks
Keep the risk register visible.
Torrent Pharmaceuticals · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
medium
U.S. Generics Pricing Pressure
U.S. revenues stable at $32M but facing headwinds from price erosion on existing ANDAs. New filings are low single-digit, making meaningful recovery unlikely in near term. EIR with VAI classification received for Pithampur facility.
GLP-1 Market Formation Uncertainty in India
Analyst raised concern about price gap between GLP-1 injectables (estimated INR 500+/month) vs generic OADs like sitagliptin (INR 150/month), questioning demand uptake. Management acknowledged demand uncertainty and noted 5x price gap could limit addressable market despite diabetes-obesity combination potential.
Market Volume Growth Muted
Market IPM volume growth near zero despite 12% Torrent India growth. Analyst asked why muted volume trends persist; management cited difficulty in explaining market-wide phenomenon but noted their chronic-focused segments haven't seen similar impact.